These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 35951643)

  • 1. JMM Profile: Fosfomycin: a potential antibiotic for multi- and extensively resistant bacteria.
    Wangchinda W; Rattanaumpawan P
    J Med Microbiol; 2022 Aug; 71(8):. PubMed ID: 35951643
    [TBL] [Abstract][Full Text] [Related]  

  • 2. An update on the management of urinary tract infections in the era of antimicrobial resistance.
    Bader MS; Loeb M; Brooks AA
    Postgrad Med; 2017 Mar; 129(2):242-258. PubMed ID: 27712137
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Fosfomycin: an old--new antibiotic.
    Raz R
    Clin Microbiol Infect; 2012 Jan; 18(1):4-7. PubMed ID: 21914036
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Inactivation of
    Hirakawa H; Takita A; Sato Y; Hiramoto S; Hashimoto Y; Ohshima N; Minamishima YA; Murakami M; Tomita H
    Microbiol Spectr; 2023 Jun; 11(3):e0506922. PubMed ID: 37199605
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Rediscovering the value of fosfomycin trometamol in the era of antimicrobial resistance: A systematic review and expert opinion.
    Cai T; Novelli A; Tascini C; Stefani S
    Int J Antimicrob Agents; 2023 Dec; 62(6):106983. PubMed ID: 37748624
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Fosfomycin: Resurgence of an old companion.
    Sastry S; Doi Y
    J Infect Chemother; 2016 May; 22(5):273-80. PubMed ID: 26923259
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Fosfomycin: In vitro efficacy against multidrug-resistant isolates beyond urinary isolates.
    Demir T; Buyukguclu T
    J Glob Antimicrob Resist; 2017 Mar; 8():164-168. PubMed ID: 28167307
    [TBL] [Abstract][Full Text] [Related]  

  • 8. New perspectives for reassessing fosfomycin: applicability in current clinical practice.
    Candel FJ; Matesanz David M; Barberán J
    Rev Esp Quimioter; 2019 May; 32 Suppl 1(Suppl 1):1-7. PubMed ID: 31131586
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Oral and intravenous fosfomycin in complicated urinary tract infections.
    López-Montesinos I; Horcajada JP
    Rev Esp Quimioter; 2019 May; 32 Suppl 1(Suppl 1):37-44. PubMed ID: 31131591
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Fosfomycin: Mechanism and Resistance.
    Silver LL
    Cold Spring Harb Perspect Med; 2017 Feb; 7(2):. PubMed ID: 28062557
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antibiotic Resistance Patterns Among Uropathogens in Female Outpatients Affected by Uncomplicated Cystitis: Focus on Fosfomycin Trometamol.
    Cai T; Verze P; Arcaniolo D; Pandolfo SD; Smarrazzo F; Manfredi C; Tascini C; Caciagli P; Lanzafame M; De Sio M; Wagenlehner F; Johansen TEB; Palmieri A
    Int J Antimicrob Agents; 2023 Nov; 62(5):106974. PubMed ID: 37739241
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The revival of fosfomycin.
    Michalopoulos AS; Livaditis IG; Gougoutas V
    Int J Infect Dis; 2011 Nov; 15(11):e732-9. PubMed ID: 21945848
    [TBL] [Abstract][Full Text] [Related]  

  • 13. In-vitro susceptibility of quinolone-resistant clinical isolates of Escherichia coli to fosfomycin trometamol.
    Ungheri D; Albini E; Belluco G
    J Chemother; 2002 Jun; 14(3):237-40. PubMed ID: 12120876
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Treatment of urinary tract infections in the era of antimicrobial resistance and new antimicrobial agents.
    Bader MS; Loeb M; Leto D; Brooks AA
    Postgrad Med; 2020 Apr; 132(3):234-250. PubMed ID: 31608743
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Fosfomycin: past, present and future].
    Baylan O
    Mikrobiyol Bul; 2010 Apr; 44(2):311-21. PubMed ID: 20549968
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effectiveness of Fosfomycin for the Treatment of Multidrug-Resistant Escherichia coli Bacteremic Urinary Tract Infections: A Randomized Clinical Trial.
    Sojo-Dorado J; López-Hernández I; Rosso-Fernandez C; Morales IM; Palacios-Baena ZR; Hernández-Torres A; Merino de Lucas E; Escolà-Vergé L; Bereciartua E; García-Vázquez E; Pintado V; Boix-Palop L; Natera-Kindelán C; Sorlí L; Borrell N; Giner-Oncina L; Amador-Prous C; Shaw E; Jover-Saenz A; Molina J; Martínez-Alvarez RM; Dueñas CJ; Calvo-Montes J; Silva JT; Cárdenes MA; Lecuona M; Pomar V; Valiente de Santis L; Yagüe-Guirao G; Lobo-Acosta MA; Merino-Bohórquez V; Pascual A; Rodríguez-Baño J;
    JAMA Netw Open; 2022 Jan; 5(1):e2137277. PubMed ID: 35024838
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Fosfomycin in infections caused by multidrug-resistant Gram-negative pathogens.
    Ruiz Ramos J; Salavert Lletí M
    Rev Esp Quimioter; 2019 May; 32 Suppl 1(Suppl 1):45-54. PubMed ID: 31131592
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Efficiency of fosfomycin trometamol for treatment of acute uncomplicated cystitis].
    Kuzmenko AV; Kuzmenko VV; Gyaurgiev TA
    Urologiia; 2018 Dec; (6):70-75. PubMed ID: 30742381
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Parenteral Fosfomycin for the Treatment of Multidrug Resistant Bacterial Infections: The Rise of the Epoxide.
    Trinh TD; Smith JR; Rybak MJ
    Pharmacotherapy; 2019 Nov; 39(11):1077-1094. PubMed ID: 31487056
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Fosfomycin for the treatment of drug-resistant urinary tract infections: potential of an old drug not explored fully.
    Patwardhan V; Singh S
    Int Urol Nephrol; 2017 Sep; 49(9):1637-1643. PubMed ID: 28616818
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.